Open company graph database — free web & API
ログイン
ログイン
01 企業検索CNID 247192
← 戻る { } JSON

MicroPort Orthopedics Inc.

マイクロポート整形外科株式会社別名
銘柄コード
—
上場市場
—
国
China
従業員（単独）
—
関連会社
1
§01

基本情報

BASIC
所在地
Zhangjiang Science City, Shanghai, China
社長
従業員数(単独)
従業員数(連結)
開始日
1998-05-15
終了日
§02

サイト

1 DOMAINS
§03

事業内容

11
Robotic surgical systems for orthopedicsClinical education and training servicesCustomer support and clinical assistanceinterventional treatment of coronary artery-related diseasescoronary stent systemsballoon cathetersOCT imaging cathetersresearch and developmentproductionmarketingservices
§04

関連会社

1 COMPANIES
会社名 Group 親会社 子会社 得意先 仕入先 業務提携 銀行等 株主等
腾冲微创微联微通健康管理有限公司
Group
リンク無しの社名は OpenBizGraph 未登録企業
§05

関連図

NETWORK
ドラッグで移動 · クリックで詳細へ
§06

沿革

105 EVENTS

MicroPort® was founded in 1998 in a small office in ZJ Hi-Tech Park in Shanghai, by a group of dedicated individuals who shared the belief that advancements in medical technology could transform patients’ lives.出典

Founded on May 15, 1998 at an incubation center in Zhangjiang Hi-Tech Park, Shanghai.出典

PTCA balloon dilatation catheter received SFDA approval, very first sale made.出典

Mustang™ bare metal stent received SFDA approval.出典

Received major funding from National Development and Reform Commission.出典

Officially entered Japan market with PTCA Balloon dilatation catheters.出典

Firebird™ drug eluting stent system received SFDA approval.出典

Mustang™ coronary stent system received CE mark.出典

Aegis Bifurcated Stent-Graft System was named National key new product.出典

Annual sales exceeded 100 million RMB.出典

Hercule® Thoracic Stent-Graft System received SFDA approval.出典

Coronary drug eluting stent implants reached over 100,000 units.出典

Firebird™ coronary drug eluting stent system won State Science and Technology Advancement Award.出典

Shanghai MicroPort Lifesciences Co., Ltd. was established, officially entered diabetes business; diversified business strategy implemented.出典

Began experimental implementation of "Vertical Integration & Horizontal Connection" management model.出典

Firebird2™ coronary drug-eluting stent system received registration approval from SFDA.出典

Shanghai MicroPort Orthopedics Co., Ltd. was established.出典

MicroPort Scientific Corporation listed on Hong Kong Stock Exchange (00853.HK).出典

Annual sales exceeded 100 million USD.出典

Shanghai MicroPort EP MedTech Co., Ltd. was established.出典

MicroPort Medical (Jiaxing) Co., Ltd. was established.出典

Undertook national R&D projects accumulating to more than 100 million RMB.出典

Shanghai MicroPort Orthopedics Co., Ltd. acquired Suzhou Best Co., Ltd.出典

Initiated “10+5” Operating Model.出典

Shanghai MicroPort® NeuroTech Co., Ltd., Shanghai MicroPort Endovascular MedTech Co., Ltd. and MicroPort Surgical (Shanghai) Co., Ltd. were established.出典

Acquired D-Pulse Medical (Beijing) Co., Ltd. and Dongguan Kewei Medical Instrument Co., Ltd.出典

MicroPort® Orthopedics Global Headquarter was established in Arlington, TX, USA.出典

Globalization Strategy Implemented.出典

Firehawk® rapamycin target eluting coronary stent system received CFDA approval.出典

WILLIS® clinical application project won State Science and Technology Advancement Award.出典

Signed joint venture agreement with Sorin Group for China's cardiac rhythm management business.出典

Acquired drug eluting stent related assets and intellectual properties from Cordis.出典

Moved into new headquarter on at 1601 Zhangdong Rd, Zhangjiang Hi-tech Park.出典

Annual sales exceeded 2 billion RMB.出典

MicroPort® Innovation Platform won State Science and Technology Advancement Award.出典

Firehawk® Rapamycin Target Eluting Coronary Stent received CE mark.出典

EVOLUTION® medial-pivot knee system received CFDA approval.出典

MicroPort Sorin CRM (Shanghai) Co., Ltd. launched China's first domestic pacemaker production line.出典

MicroPort Suzhou OrthoRecon Co., Ltd. and MicroPort Suzhou Orthopedic Instruments Co., Ltd. were established in Suzhou Industrial Zone.出典

MicroPort Surgical Robotics Co., Ltd. and MicroPort Online Co., Ltd. were established.出典

Founded in 2015, MicroPort出典

New Technology and Clinical Application of Minimally Invasive Cardiac Surgery project won the State Science and Technology Advancement Award.出典

Proposed to acquire the cardiac rhythm management business of LivaNova for $190 million in cash.出典

AAA/TAA stent graft series product critical technical development and large-scale industrialization won State Science and Technology Award.出典

Rega® Family Implantable Pacemakers and Firefighter™ PTCA Balloon Catheters received CFDA approval.出典

The data of Firehawk® TARGET AC clinical trial showed the 3-month stent strut cover rate was of 99.9%, 5-year follow-up data of TARGET I RCT showed stent thrombus rate was 0.出典

Medial-Pivot Knee arthroplasty system demonstrated high survivorship (98.8%) and patient satisfaction (95%) in a 17-year follow-up study.出典

Firesorb® pivotal study FUTURE II trial completed first enrollment.出典

MicroPort® CardioFlow brought in strategic investors.出典

MicroPort® EP quoted on NEEQ.出典

MicroPort Urocare Co., Ltd. established, marking the company's official entry in urology and gynecology sectors.出典

MicroPort® Jiaxing park established.出典

Acquired Brazil distributors to implement localized management on the Brazil market.出典

Firehawk® clinical data from the Target AC European clinical trial has been accepted for publication in the prestigious medical journal The Lancet.出典

Tubridge® Vascular Reconstruction Device was launched.出典

Firehawk® and Firebird2® gained regulatory approval in Taiwan.出典

First implantation of Rega® Family Implantable Pacemakers.出典

Global aggregated implantations of coronary artery stent system, artificial joint implants and pacemakers reached 4.5 million, 1.1 million and 1 million respectively.出典

MicroPort® CRM global headquarter was established in Clamart, France.出典

MicroPort Orthopedics (Suzhou) Co., Ltd. was established.出典

Every 12 seconds, a MicroPort® product was used across the world.出典

SoSuperior™ Medial Stability Total Knee Replacement System and Aspiration™ Medial Pivot Total Knee Replacement System gained approval in China.出典

MicroPort® Obtained CE Mark for Firehawk Liberty™, a New Generation Rapamycin Target Eluting Coronary Stent System.出典

The 24 months results of the Firehawk® TARGET AC trial were announced in EuroPCR 2019, and would be published in the Journal of the American College of Cardiology (JACC).出典

Every 6 seconds, a MicroPort® product was used across the world.出典

The MicroPort Group and its associated companies introduced external financing of over US$1 billion accumulatively and widely recognized by the capital market.出典

MicroPort® CardioFlow Medtech was listed on the Main Board of the Hong Kong Stock Exchange出典

MicroPort® MedBot® was listed on the Main Board of the Hong Kong Stock Exchange出典

MicroPort® CRM introduced the Alizea™ and Borea™ pacemakers equipped with Bluetooth technology and the SmartView Connect™ home monitor in Europe.出典

MicroPort® CRM Navigo™ left ventricular pacing leads received CE mark approval in Europe出典

MicroPort NeuroTech™ U-track Intracranial Support Catheter System became commercially available in the market出典

EverPace Disposable Cardiac Mapping Leads became commercially available in the market出典

Firefighter™ and Foxtrot® Pro PTCA Balloon Dilatation Catheter approved for marketing in Pakistan and Bosnia and Herzegovina出典

HorizonMedical™ Daylily® Embryo Transfer Catheter approved for marketing in Thailand出典

Four products including Firehawk® Stent and Firefighter™ PTCA Balloon Dilatation Catheter received registration and marketing approval in Saudi Arabia出典

Firefighter™ NC received registration approval in Taiwan.出典

MicroPort NeuroTech was listed on the Main Board of the Hong Kong Stock Exchange出典

MicroPort MedBot Skywalker™ Orthopedic Surgical Robot received NMPA approval in China, FDA 510(k) approval in the US and CE mark approval in Europe出典

MicroPort NeuroTech Diveer® Intracranial Balloon Catheter, Neurohawk® Stent Thrombectomy Device, X-track® Intracranial Distal Access Catheter, and NUMEN Silk® 3D Electronically Detachable Coil received NMPA approvals in China出典

MicroPort MedBot Toumai® Laparoscopic Surgical Robot received NMPA approval in China and won several awards出典

MicroPort® CRM Invicta™ Defibrillation leads received CE mark approval in Europe出典

MicroPort Endovascular Talos® Thoracic Stent Graft System received NMPA approval in China出典

MicroPort Urocare Single-use Flexible Digital Ureteroscope received the NMPA approval in China出典

MicroPort Argus™ intravascular OCT system received NMPA approval in China出典

MicroPort® inaugurated a training Center in Brazil出典

MicroPort® obtained 4 FDA approvals, including: MicroPort® Orthopedics EVOLUTION® Tibial Cones出典

58 products obtained NMPA's approval in China, including: MicroPort® Orthopedics Evolution® CCK Knee Revision System出典

And 6 products entered NMPA's "Green Path", including: MicroPort® Orthopedics Wrist Arthroplasty System出典

MicroPort® CardioFlow completed a strategic merger with MicroPort® CRM, building a comprehensive heart failure management solution spanning all etiologies, stages, and treatment pathways.出典

MicroPort® obtained 7 FDA approvals, including: MicroPort® Orthopedics NEXUS® Femoral Stem.出典

MicroPort® obtained 23 CE approvals, including: MicroPort® Endovastec™ Hector® Multi-Branch Thoracic Stent Graft System (custom certification).出典

MicroPort® obtained 23 CE approvals, including: MicroPort EverPace™ IceMagic™ Cryoablation System.出典

MicroPort® obtained 23 CE approvals, including: MicroPort® CRM MR-Conditional Mixed Pacing System and VEGA™ M lead.出典

Over 30 products received NMPA Class III medical device registration, including: MicroPort® Coronary TomaHawk® Intravascular Lithotripsy Catheter and Firelimus® Drug-Eluting Balloon, MicroPort® CardioFlow AnchorMan® Left Atrial Appendage Closure System, MicroPort® CRM TEN Series 3.0T MRI-Conditional Pacemakers, MicroPort® Endovastec™ Cratos™ Thoracic Branch Stent Graft, MicroPort EverPace™ PulseMagic™ TrueForce® PFA Catheter, MicroPort® MedBot UniPath® Surgical Navigation System and Toumai® SP Single-Port Robot, MicroPort® VisionPower YINI® Cataract Phacoemulsification System, MicroPort® MicroVasive EZ-Eye™ 5100 GI Endoscopy System, MicroPort® Dentition YairDent® Dental Implant System.出典

41 products were accepted into the NMPA’s 'Green Path', including: MicroPort® Endovastec™ Hector® Multi-Branch Thoracic Stent Graft, MicroPort® UniFlow Streamliner™ Implantable Tibial Nerve Stimulator, MicroPort EverPace™ EasyEcho™ Intracardiac Ultrasound Catheter, MicroPort NeuroScientific StraitPass™ Disposable Hematoma Aspiration Device.出典

MicroPort® CRM VEGA™ M58 Pacing Lead approved in Australia, MicroPort® CardioFlow VitaFlow Liberty® Transcatheter Aortic Valve System approved in 15 countries, including Brazil and Morocco, MicroPort® MedBot Toumai® Remote Surgery System approved in 10 countries.出典

TARGET-FIRST Trial results for MicroPort® Coronary Firehawk® Stent published in The New England Journal of Medicine and presented at ESC 2025, demonstrating safety of 1-month DAPT in low-risk AMI patients with complete revascularization.出典

MicroPort® Coronary surpassed 10 million stent systems shipped and implanted globally.出典

MicroPort® MedBot Toumai® Surgical Robot achieved over 100 global commercial installations.出典

The Toumai® system also achieved multiple robotic surgery milestones, including: The world’s first commercial remote robotic surgery.出典

The Toumai® system also achieved multiple robotic surgery milestones, including: The first FDA-IDE approved remote robotic surgery.出典

The Toumai® system also achieved multiple robotic surgery milestones, including: The first remote robotic surgery in Europe.出典

The Toumai® system also achieved multiple robotic surgery milestones, including: The first ultra-remote 5G robotic surgery at over 4,500 meters altitude.出典

The Toumai® system also achieved multiple robotic surgery milestones, including: The first low-orbit satellite remote surgery.出典

MicroPort® CardioFlow’s VitaFlow Liberty® Expands Global Presence with Key Milestones in Europe and Latin America出典

§07

ニュース

0 ARTICLES

ニュースはありません。

§09

出典・更新

SOURCES
DOMAIN単独ドメイン：あり
UPDATED2026-09-28 23:11 · Model: ggml-org/gpt-oss-20b
↑